Toward a Precision Treatment Approach for Metabolic Depression: Integrating Epidemiology, Neuroscience, and Psychiatry
Biological Psychiatry Global Open Science · 2023-10 · 3 (4) · 623-631
DOI: 10.1016/j.bpsgos.2023.08.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological Psychiatry Global Open Science, 2023-10. Verfasst von Kathleen Watson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neuroscience in Women's Health, Stanford University, Palo Alto, California. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, Hope for Depression Research Foundation, National Institutes of Health.
Themen: Depression
Abstract (Originalsprache)
Background
Individuals with comorbid major depressive disorder and type 2 diabetes represent an important subgroup of patients for whom conventional treatment may be insufficient. A precision treatment approach that addresses insulin resistance with an outcome of a positive response to antidepressants may prove beneficial.
Methods
This study utilized an emulated target trial on a large dataset from the Optum Clinformatics Data Mart Database. We evaluated the effect of adjuvant pioglitazone, an insulin-sensitizing drug, on antidepressant response among 4696 people with type 2 diabetes, comparing it with DPP4 (dipeptidyl peptidase-4) inhibitors (non-insulin-sensitizing). An additional analysis involving 6518 participants was conducted to assess the efficacy of pioglitazone versus sulfonylureas.
Results
The instrumental variable analysis indicated that the initiation of an antidepressant with pioglitazone was superior to DPP4 inhibitors in terms of antidepressant response, with fewer treatment shifts and/or additions of new antidepressant or antipsychotic over a 1-year period. This result was consistent when pioglitazone was compared with sulfonylureas in a supplemental analysis.
Conclusions
Our findings suggest that pioglitazone may be more effective than DPP4 inhibitors or sulfonylureas in enhancing antidepressant response among people with comorbid major depressive disorder and type 2 diabetes. This provides a strong case for the use of pioglitazone in patients with these conditions, emphasizing the potential of precision medicine strategies. The results should be interpreted with caution due to inherent limitations associated with observational data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Neuroscience in Women's Health, Stanford University, Palo Alto, California.
- Michigan Neuroscience Institute, University of Michigan, Ann Arbor, Michigan.
Förderung
- NCATS NIH HHS
- Hope for Depression Research Foundation
- National Institutes of Health
- Stanford University
Zitieren
APA
Watson, K., Akil, H., & Rasgon, N. (2023). Toward a Precision Treatment Approach for Metabolic Depression: Integrating Epidemiology, Neuroscience, and Psychiatry. Biological Psychiatry Global Open Science, 3(4), 623-631. https://doi.org/10.1016/j.bpsgos.2023.08.008
Vancouver
Watson K, Akil H, Rasgon N. Toward a Precision Treatment Approach for Metabolic Depression: Integrating Epidemiology, Neuroscience, and Psychiatry. Biological Psychiatry Global Open Science. 2023;3(4):623-631. doi:10.1016/j.bpsgos.2023.08.008
BibTeX
@article{Watson2023,
author = {Watson, Kathleen and Akil, Huda and Rasgon, Natalie},
title = {Toward a Precision Treatment Approach for Metabolic Depression: Integrating Epidemiology, Neuroscience, and Psychiatry},
journal = {Biological Psychiatry Global Open Science},
year = {2023},
volume = {3},
number = {4},
pages = {623--631},
doi = {10.1016/j.bpsgos.2023.08.008}
}
EUVIMED